An employee stacks Johnson& Johnson Neosporin brand boxes on the production line at the J&J consumer healthcare products plant in Lititz, Pennsylvania, the United States. [Photo/Agencies] New drugs developed by pharmaceutical companies from the United States have played an important role in improving healthcare for Chinese, according to China Association of Enterprises with Foreign Investment. International pharmaceutical companies, including those from the US, have kept investing in research and development of new drugs in China, which has also contributed to improved innovation and research capabilities for domestic pharmaceutical companies, said Zuo Yuzeng, chief for communications at the association's R& D-based Pharmaceutical Association Committee. The committee is comprised of 40 international companies with pharmaceutical research and development capabilities, including 12 from the US, such as MSD and Xian Janssen, he said. The companies have brought many patent drugs to Chinese patients. Many were not available in China before, and have contributed to helping patients relieve pain and prolong life, the committee said. A recent new drug that was introduced to China was Sirturo, developed by Xian Janssen Pharmaceutical, a subsidiary of US company Johnson& Johnson. The drug, the first new medication for tuberculosis worldwide for the past 45 years, has been administered in China since Feb 24, and initial results showed it is effective for patients with multidrug-resistant TB, according to Wang Bin, deputy head of disease control and prevention for the National Health Commission. Asgar Rangoonwala, president of Xian Janssen, said the drug is now being used at 16 hospitals nationwide in a trial program. In April, China Drug Administration approved a nine-way HPV vaccine, which works against up to nine types of HPV and was developed by US company MSD. A similar vaccine, which was also developed by the company and works against four types of HPV, was approved by the administration in May last year. Previously, no vaccines were available on the Chinese mainland to effectively prevent cervical cancer, the second most common cancer among Chinese women aged 15 to 44 after breast cancer, except a two-way HPV vaccine, driving many women to Hong Kong to receive such vaccines. International pharmaceutical companies have also contributed to improved capacities in innovation and research of domestic companies through increasing research and development in China, partnering with domestic research institutes and providing training, according to R & D-based Pharmaceutical Association Committee. Some domestic international companies in recent years have been developing fast and they are catching up, said Zuo from the committee. uv braceletglow in the dark wristbands ukwellies and wristbands 2017rubber wristbandsrubber wristbands in bulkmake your own rubber bracelet
A J-20 fighter joins a drill in this undated photo. The aircraft is working with other jet types on joint attacks.Yang Jun / Xinhua The People's Liberation Army Air Force has begun training its pilots a new airstrike tactic that involves all of its best fighter jets. An Air Force aviation unit in northwestern China, the first to use the PLA's most advanced fighter jet, the J-20, has recently been performing joint tactical exercises with J-16 and J-10C aircraft, according to the Air Force. In the exercises, the radar-evading J-20s take advantage of their situational awareness and stealth abilities to seize air superiority. Then J-16s and J-10Cs launch long-range precision strikes against land targets. The J-20 has displayed not only overwhelming air combat superiority in the drills, but also a crucial ability to clear the path for and coordinate combat with other types of fighter jets, the Air Force said in a statement. It added that many pilots in the unit are able to fly all of the three top planes. He Xing, a pilot taking part in the drills, was quoted by the statement as saying that the unit's pilots are trained to operate J-20, J-16 and J-10C to familiarize themselves with the aircraft and get to know their strengths and weaknesses. Then we will be able to know how to use the advantages of a certain type of plane to complement other models and how to make the best use of each aircraft, he said. Yang Wei, chief designer of the J-20 at Aviation Industry Corp of China, said in a China Central Television program about the exercises that the J-20 was designed to carry out strike operations to help obtain air combat superiority. The J-20, the first of China's fifth-generation combat aircraft, made its maiden flight in January 2011 and was declassified in November 2016. It started to be commissioned to the Air Force in 2017, becoming the third stealth fighter jet to enter service, after the United States' F-22 Raptor and F-35 Lightning II. It has been sent to take part in a series of combat exercises and has practiced beyond-visual-range aerial fighting maneuvers during the drills, according to the Air Force. The jet bears the important responsibility of clearing a path for other aircraft in an air battle, according to Zhang Hao, head of an Air Force flight-testing center that has deployed the jet. The J-16 and J-10C are also among China's latest combat aircraft and were developed by Chinese designers. They were delivered to the Air Force around 2017, according to the Air Force.
